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Enterovirus D68 Subclade B3 
Strain Circulating and Causing an 
Outbreak in the United States in 
2016
Guiqing Wang1,2, Jian Zhuge2, Weihua Huang1, Sheila M. Nolan3, Victoria L. Gilrane1, 
Changhong Yin1, Nevenka Dimitrova4 & John T. Fallon1,2
In 2014 the United States experienced a nationwide outbreak of Enterovirus D68 (EV-D68) infection. 
There were no confirmed cases of EV-D68 in 2015 and CDC was only aware of limited sporadic EV-D68 
detection in the US in 2016. In this report, we analyzed 749 nasopharyngeal (NP) specimens collected in 
2015 and 2016 from patients in the Lower Hudson Valley, New York using a previously validated EV-D68-
specific rRT-PCR assay. EV-D68 was detected in none of 199 NP specimens collected in 2015, and in one 
of 108 (0.9%) samples from January to May and 159 of 442 (36.0%) samples from July to October 2016. 
Complete EV-D68 genome sequences from 22 patients in 2016 were obtained using a metagenomic 
next-generation sequencing assay. Comparative genome analysis confirmed that a new EV-D68 strain 
belonging to subclade B3, with 3.2–4.8% divergence in nucleotide from subclade B1 strains identified 
during the 2014 US outbreak, was circulating in the US in 2016 and caused an outbreak in the Lower 
Hudson Valley, New York with 160 laboratory-confirmed cases. Our data highlight the genetic variability 
and capacity in causing outbreak by diverse EV-D68 strains, and the necessity of awareness and more 
surveillance on their active circulation worldwide.
Enteroviruses in the family Picornaviridae are small, non-enveloped viruses with a single-stranded, positive-sense 
RNA genome of approximately 7.5 kilobases1, 2. The genus Enterovirus contains seven species, including entero-
virus A to D and rhinovirus A to C that commonly cause human disease2, 3. Enterovirus D68 (EV-D68) was first 
recovered from patients with respiratory illness in California in 19624 and was infrequently recognized until its 
recent emergence worldwide5, 6. In the United States, only 26 cases had been reported to the Centers for Disease 
Control and Prevention (CDC) from 1970 through 20057.
The emergence of EV-D68 infection in patients with acute respiratory illness was first observed in the 2000’s 
in Asia, Europe and a few US states5, 8–12. In late summer/fall 2014, a nationwide outbreak of severe respiratory 
illness associated with EV-D68 was noticed from 49 US states with at least 1,153 confirmed cases13, 14. Also, 120 
cases of acute flaccid myelitis (AFM), which coincided with this outbreak, were reported from 34 US states from 
August through December 201415–18. An increase of EV-D68 cases was also documented in Canada, Eurasia and 
Australia in 20146, 19–23. The US laboratories reported zero EV-D68 detections to CDC’s National Enterovirus 
Surveillance System (NESS) during the 2015 enterovirus season (summer and fall)13. CDC is only aware of lim-
ited sporadic EV-D68 detection in the US in 2016, although an increase of AFM cases from 21 in 2015 to 136 
in 2016 was observed18. Most recently, an upsurge of EV-D68 infection in 2016 was noticed in several European 
countries, including the Netherlands24, France25 and Sweden26, with additional sporadic cases from the UK, Italy, 
Portugal and Germany27.
Genetic analysis of earlier EV-D68 strains collected between 1962 and 2011 has revealed that three lineages 
(lineages 1 to 3) or clades (clades A to C) of EV-D68 were circulating worldwide5, 9, 28. During and after the 2014 US 
outbreak, novel clade and subclades of EV-D68 strains, including subclades B1 to B315, 29–31 and a new EV-D68 clade 
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D32, have been identified and proposed. Sequence analyses of the EV-D68 strains collected in the US in 2014 showed 
two subclades (a major subclade B1 and a minor subclade B2) co-circulating at the time of the outbreak14, 15, 29, 33  
(Wang et al., unpublished data). Midgley et al. reported that 92% of 606 cases analyzed had infection with sub-
clade B1 strains, while subclade B2 strains accounted for 7% of EV-D68 cases in the 2014 outbreak14. One strain 
(US/KY/14-18953) is distantly related to subclades B1 and B214 and has now been classified as clade D32. No 
EV-D68 strain belonging to clade A, clade C and subclade B3 has been identified in the 2014 US outbreak.
The Lower Hudson Valley, New York is located immediately north of New York City and consists of seven 
counties (Westchester, Putnam, Dutchess, Orange, Rockland, Ulster, and Sullivan counties) with approximately 
three million residents. During the 2014 nationwide EV-D68 outbreak, we reported 94 cases with severe res-
piratory illness from this region using an EV-D68-specific real-time reverse-transcription PCR (rRT-PCR)34 
and a shotgun next-generation sequencing (NGS) assay35. We and other investigators also revealed that a novel 
clade of EV-D68 strain, now known as subclade B1, was responsible for the 2014 outbreak based on compar-
ative genome analysis15, 29, 33. No EV-D68 case was confirmed in our facility in 2015. Recently, we noticed an 
increased number of patients with severe respiratory illness associated with EV-D68 infection in the Lower 
Hudson Valley, New York36. Our further investigation confirmed this regional outbreak of EV-D68 infection 
with 160 laboratory-confirmed cases in the US in 2016. In this report, we provided detailed epidemiology, viral 
genomics and clinical characteristics of EV-D68 cases identified from this outbreak. Strikingly, our comparative 
genome analysis suggests that a new EV-D68 strain belonging to subclade B3 was circulating in the US in 2016 
and caused this outbreak.
Results
Detection of RhV/EV by FilmArray RP assay, 2014–2016. From January 2014 to October 2016, a 
total of 11,715 NP specimens were analyzed by FilmArray RP assay at the WMC Clinical Virology Laboratory. 
The overall positivity by the RP assay were 49.4%, with approximately 25% of these NP samples were positive to 
RhV/EV (Table 1). The overall RhV/EV positivity rates were comparable during the period from 2014 to 2016.
The weekly distribution of RhV/EV-positive NP specimens from 2014 through October 2014 analyzed by 
the FilmArray RP assay is shown in Fig. 1. Typically, a minor peak of RhV/EV positives in the spring and early 
summer, followed by a major peak during autumn and early winter, were observed each year. The major peak 
observed in September and October 2014 corresponded to the US nationwide EV-D68 outbreak. A similar peak 
for RhV/EV positivity was also observed in 2015 from September through December. The spring-summer peak 
of RhV/EV positive in 2016 appeared higher than that in 2014, but the autumn-winter peak in 2016 was lower 
than that in 2014.
Detection of EV-D68 by rRT-PCR, 2014–2016. In 2014, a total of 322 NP specimens were analyzed 
by rRT-PCR and DNA sequencing of partial VP1 gene and 5′ untranslated region; EV-D68 were detected in 95 
patients as we previously reported34, 35. In a subsequent follow-up study, 199 NP specimens collected in September 
and October 2015 were examined retrospectively using the same rRT-PCR assay. One hundred eighty-six 
(n = 186) of these samples, including 140 RhV/EV-positive and 46 RhV/EV-negative NP specimens, were also 
Month & year
Total no. 
by RP No. of positivea Positivity (%)
No. of RhV/
EV positive
RhV/EV 
positivity (%)
Jan-Dec 2014 3,762 1,769 47.0 917 24.4
Jan-Dec 2015 4,310 2,131 49.4 1,034 24.0
Jan-Oct 2016 3,643 1,882 51.7 985 27.0
Total 11,715 5,782 49.4 2,936 25.1
Table 1. Number of nasopharyngeal specimens examined by FilmArray RP during the period from 2014 to 
2016. aOne or more target(s) detected by the FilmArray RP assay.
Figure 1. Weekly distribution of RhV/EV-positive nasopharyngeal (NP) specimens detected by the FilmArray 
Respiratory Panel assay, 2014 through October 2016.
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examined by the NGS assay. None of these specimens in 2015 was positive to EV-D68 by either rRT-PCR or NGS 
assay, although multiple other respiratory viruses and bacteria were detected by the NGS assay (data not shown).
From January 1 to October 31, 2016, a total of 985 (27.0%) NP specimens from 861 patients were positive to 
RhV/EV by the RP assay. One hundred twenty-four (n = 124) NP specimens were duplicated or repeated and 
were removed from this analysis. Of 861 remaining RhV/EV-positive NP specimens, 416 (48.3%) were collected 
from January through May 2016 and 445 (51.7%) were collected from June through October 2016.
For EV-D68 rRT-PCR analysis, 108 of 416 (26.0%) representative RhV/EV-positive NP specimens collected 
from January through May 2016 were randomly selected, approximately 20 samples from each month. EV-D68 
was detected by rRT-PCR in one of 108 (0.9%) RhV/EV-positive NP specimens collected from January through 
May 2016. The only EV-D68-positive sample was collected from a pediatric patient at the end of January 2016.
All but three (442 of 445, 99.3%) RhV/EV-positive NP specimens collected from June through October 2016 
were selected and analyzed by rRT-PCR. One hundred fifty-nine (n = 159, 36.0%) of these NP specimens were 
positive to EV-D68 (Table 2).
Overall, EV-D68 was detected in respiratory samples of 254 patients by analyzing 1,096 NP specimens col-
lected from 2013 to October 2016. Notably, EV-D68 was only detected in patients during the 2014 outbreak 
(n = 94) and the most recent upsurge in the Lower Hudson Valley in 2016 (n = 160). The temporal distribution 
of EV-D68 cases from 2013–2016 and geographic distribution of laboratory-confirmed EV-D68 cases in 2016 are 
shown in Fig. 2.
Clinical characteristics of patients with EV-D68 in 2016. The median age of 160 patients from whom 
EV-D68 were detected was 3.2 years (3 weeks to 91 years) and 100 (62.5%) were male. Of these, 145 (90.6%) were 
pediatric patients with age ≤ 21 years and 15 (9.4%) were adult. The median age for pediatric patients was 2.6 
years (3-week to 19-year old). Clinical data from 104 pediatric patients with specimens collected from June to 
mid-September were reviewed: the common clinical presentations included fever (n = 73, 70.2%), cough (n = 75, 
72.1%), wheezing (n = 53, 51%), and increased work of breathing (n = 61, 58.6%). Thirty-seven (35.6%) had a 
prior history of asthma. Thirty-one of 104 (29.8%) pediatric patients required intensive care unit admission in 
2016, comparable to 23 of 80 (28.8%) pediatric patients in 2014 (p = 0.8712). We had no AFM cases in 2014, but 
had two cases thus far in 2016; both were positive for EV-D68 in NP specimens and were in very young children 
Month in 2016
No. of 
RhV/EV- 
positive
No. tested by 
rRT-PCR (%)
EV-D68 rRT-PCR
No. of negative No. of positive Positivity (%)
Jan-May 416 108 (26.0) 107 1 0.9
June 71 70 (98.6) 39 31 44.3
July 86 86 (100) 60 26 30.2
August 80 79 (98.8) 28 51 64.6
September 96 96 (100) 58 38 39.6
October 112 111 (99.1) 98 13 11.7
Total 861 550 (63.9) 390 160 29.1
Table 2. Number of nasopharyngeal specimens examined by the FilmArray Respiratory Panel and EV-D68 
rRT-PCR from January to October 2016.
Figure 2. (A) Enterovirus D68 detected by an EV-D68-specific rRT-PCR assay in nasopharyngeal (NP) 
specimens collected from 2013 through October 2016; (B) Map of counties in the Lower Hudson Valley, New 
York and distribution on the number of patients with enterovirus D68 detected from respiratory samples in 
2016. One hundred forty-nine (n = 149) of 160 (93.1%) confirmed cases in 2016 were from this region. The star 
indicates the site of the Westchester Medical Center. Map was adapted with permission from the New York State 
Department of Environmental Conservation website (http://www.dec.ny.gov/outdoor/7804.html).
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(5 months and 21 months of age, respectively). Of 15 adult patients, eight had clinical data available and five of 
them had respiratory symptoms.
Phylogenetic analysis of 2016 US EV-D68 strains. A total of 22 complete or nearly complete EV-D68 
genomes were obtained from respiratory specimens of patients during the 2016 outbreak in the Lower Hudson 
Valley, New York. Nine of these from our first NGS run were published recently36. Additional 13 were assem-
bled from two subsequent NGS runs. Comparative genome analysis of 341 EV-D68 genomes available from the 
GenBank, including 22 from this study and three from 2016 patients in Florida, Texas and New York as reported 
by the CDC37, suggested that a novel EV-D68 strain belonging to subclade B3 was circulating in the US in 2016. 
As shown in Fig. 3 and Supplemental Figure S1, all 25 EV-D68 strains from the US in 2016 belonged to subclade 
B3, which were most closely related to two recent EV-D68 strains detected in Southern China in 2015 with 98.7–
99.0% identity in nucleotides. The 23 additional EV-D68 strains from China and Taiwan all belonged to subclade 
B3 but were grouped into a separate subclutster.
The average genome divergence was 4.3% (ranging 3.2–4.8%) in nucleotides between EV-D68 subclade B3 
strains from the US in 2016 and those of subclade B1 strains causing the 2014 US outbreak. This converted to 
an average of approximately 320 nucleotide difference per genome between subclades B3 and B1. The detailed 
nucleotide and amino acid sequence identity between subclade B3 and other subtypes of EV-D68 strains are 
summarized in Table 3.
A total of 28 amino acid polymorphisms were identified between subclade B3 strains from 2016 and B1 from 
2014 in the US on basis of the complete polypeptide sequences of approximately 2,190 amino acids (Fig. 4). 
Among these, seven amino acid substitutions (T143, I480, T770, I898, M1209, A1384 and D1598) were first rec-
ognized in this study and were predominantly seen in subclade B3 strains from the US in 2016.
Figure 3. (A) Collapsed phylogenetic tree of enterovirus D68 based on nucleotide sequences of 341 complete or 
nearly complete genomes. Please refer to supplemental Figure S1 for a detailes phylogenetic tree with sequence 
accession numbers and strain information. Strains of EV-D70 and EV-D90 were used as outgroup; (B) An 
enlarged phylogenetic tree of EV-D68 subclade B3 strains (n = 50). Strains from China (CHN) and Taiwan 
(TWN) were shown in red and pink, respectively, whereas strains from the US were shown in green. One strain 
representing each of other subtypes (clades A, C and D, subclades B1 and B2, and prototype) was included for 
comparison. The numbers at each branch node are the % of nucleotide sequence identify.
www.nature.com/scientificreports/
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Discussion
In 2014, the US experienced a nationwide outbreak of EV-D68 associated with severe respiratory illness. In addi-
tion to the 1,159 confirmed cases of EV-D68 infection reported from 49 states, CDC estimates that there were 
likely millions of mild EV-D68 infections during this outbreak for which people did not seek medical treatment 
and/or get tested. Surprisingly, no confirmed cases of EV-D68 infection was reported in 2015 and CDC has 
noticed only limited sporadic cases in the US as of October, 201613. In this study, we reported an EV-D68 outbreak 
in the Lower Hudson Valley, New York in 2016. To the best of our knowledge, this represents the first report of 
an outbreak of EV-D68 infection in the US in 2016 with at least 160 laboratory-confirmed cases. An increase of 
AFM cases was co-incident with the EV-D68 nationwide outbreak in 2014, and in fact, the number of AFM cases 
reported to CDC in 2016 increased from 25 cases in 2015 to 108 cases as of October 2016. We speculate that the 
increased reports of AFM cases in 2016 may indicate many undetected or unreported EV-D68 cases in the US 
since EV-D68 infection is not a national notifiable disease, not routinely tested in clinical laboratories, and none 
of the FDA-cleared multiple PCR assays for respiratory pathogens differentiates EV-D68 from other rhinovirus 
and/or enteroviruses. Since sporadic EV-D68 cases in other US states have been confirmed by CDC, clinicians 
and public health agencies should be aware of the active circulation of EV-D68 in the US in 2016.
The 2016 EV-D68 outbreak in the Lower Hudson Valley, New York is most likely the first upsurge of EV-D68 
infection in this region since 2014. This is evident by none of 199 NP specimens collected during the typical 
endemic months (September to October) in 2015 being positive for EV-D68, and EV-D68 was detected in only 
one of 108 (0.9%) randomly selected RhV/EV-positive NP specimens collected from January through May 2016. 
In contrast, 159 of 442 (36.0%) RhV/EV-positive NP specimens collected from June 1 through October 30, 2016 
were positive to EV-D68 as confirmed by EV-D68-specific rRT-PCR and/or NGS assay. It is noteworthy that 
higher EV-D68 positivity rate was observed in 2016 among RhV/EV-positive NP specimens (36%, 159/422), 
compared to that seen during the 2014 outbreak (29.2%, 94/322). Nonetheless, we and other medical facilities in 
this region did not report significant increase in patients of emergency department visit or pediatric intensive care 
unit admission for respiratory disease during this regional EV-D68 outbreak. This can be in part explained by two 
factors as demonstrated in Fig. 1: the smaller number of RhV/EV-positive patients observed during typical peak 
RhV/EV months and the extended outbreak period from June through October in 2016.
Comparative analysis of 22 complete or nearly complete genomes of EV-D68 strains obtained in this study 
with those available from the GenBank confirms that the EV-D68 strains causing the 2016 outbreak in the Lower 
EV-D68 
clade
Sequence identity range (%)
Nucleotide, 
genome
Nucleotide, 
VP1
Amino acid, 
polyprotein
Amino 
acid, VP1
B3 vs. A 90.7–91.0 87.8–88.9 98.1–98.2 95.9–97.1
B3 vs. B1 95.5–95.8 95.4–96.5 99.0–99.3 98.6–99.4
B3 vs. B2 93.8–94.2 93.2–94.5 99.2–99.5 99.1–99.8
B3 vs. C 92.0–92.4 90.8–92.2 98.8–99.1 96.6–97.8
B3 vs. D 89.7–89.9 97.3–88.8 98.2–98.3 96.4–97.4
B3 vs. 
Fermon 87.7–88.1 85.3–86.7 97.6–97.7 94.0–95.0
Table 3. Nucleotide and amino acid sequence identity between subclade B3 and other subtypes of EV-D68 
strainsa. aBased on comparisons of 50 complete genomes of subclade B3 strains and representative strains from 
other clades and subclades of enterovirus D68. See Fig. 3 for a list of strains included.
Figure 4. Amino acid (aa) polymorphisms of Enterovirus D68 subclade B3 based on the entire polypeptide 
sequences of approximate 2,190 aa. Twenty-eight amino acid polymorphisms were identified in subclade B3 
strains from the US in 2016, as compared to those of subclade B1 strains from US in 2014. Of these, 7 amino 
acid substitutions that were first described in this report are highlighted in red with corresponding amino acid 
position numbers. See Fig. 3 for a list of subclade B3 strains included (n = 50). Twenty subclade B1 strains from 
New York in 2014 were used to generate the graphic presentation for the B1_USA. Amino acid position was 
based on the EV-D68 subclade B1 strain NY120 (accession #:KP745751).
www.nature.com/scientificreports/
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Hudson Valley, New York belong to a novel subclade B331. Most recently, CDC reported three genome sequences 
from three patients, two with confirmed AFM from Florida and Texas and one with suspected AFM from New 
York, in 201637. Our EV-D68 strains showed high identity (99.1–99.8% in nucleotide) to the three CDC strains; 
all 25 EV-D68 strains reported from the US in 2016 clustered into a tight sub-branch of the subclade B3 in the 
phylogenetic tree, suggesting that the same EV-D68 strain is circulating in the US in 2016, with 4.3% (ranging 
3.2–4.8%) nucleotide divergence from subclade B1 strains causing the 2014 outbreak. An upsurge of subclade 
B3-associated EV-D68 infection in 2016 has recently been reported in the Netherlands24 and Sweden26. Due to 
the lack of complete genome sequences from the Netherlands and Sweden B3 strains, it is difficult to estimate 
the overall genetic similarity between B3 strains from the US and Europe. However, the capability of EV-D68 
subclade B3 strains in causing outbreak in multiple countries in 2016 raises a concern on its future spread and 
potential to cause a global pandemic.
It is unknown if EV-D68 subclade B3 represents a strain totally different from the subclade B1 strain, or it 
constitutes a strain evolved from the subclade B1 strain causing the 2014 outbreak. Taraz et al. estimated that the 
mean rate of nucleotide substitution for the VP1 gene in EV-D68 was 6.2 × 10−3 substitutions per site/year5. Since 
the VP1 is the gene with highest genetic diversity in the EV-D68 genome, one may expect that the maximum 
nucleotide substitution would be no more than ~47 nucleotides per year over the approximately 7.5-kb genome. 
The average nucleotide divergence between B1 and B3 strains is 4.3%, which converts to difference of ~320 nucle-
otides. To reach this, it would take about 6.7 years to accumulate based on the substitution rate estimated above. 
Therefore, the subclade B3 strains circulating in the US and Europe in 2016 most likely represented a newly 
emerging virus strain, rather than a continuum of mutation from the subclade B1 strains responsible for the 2014 
US outbreak. Limited evidence suggests that EV-D68 subclade B3 has emerged only in recent years, with the 
earliest complete genome retrieved in a 2013 sample from China (accession number: KT803590)22. No EV-D68 
subclade B3 strains had been identified in the US until 2016, although it appeared to be predominant in patients 
of China and Taiwan in 201422, 31.
Several clinical characteristics have been noticed among our patients with EV-D68 subclade B3 infection 
in 2016. First, subclade B3 was capable of causing severe respiratory illness as subclade B1 was during the 2014 
outbreak. This is evident by the number of pediatric patients who required intensive care unit admission (31 of 
104, 29.8% in 2016 versus 23 of 80, 28.8% in 2014, p = 0.8712). Second, the median age of pediatric patients was 
2.8 years in 2016, versus 5 years in 2014, which might indicate partial immunity acquired through asymptomatic 
infection during the 2014 outbreak in older children. Third, subclade B3 was detected in 15 adult patients in 2016, 
while the majority remained to be pediatric patients. In contrast, all our cases in 2014 outbreak were pediatric 
patients. Last, we had no cases of AFM in 2014, but had two AFM cases with EV-D68 infection in 2016. Although 
the cause of these AFM cases has not yet determined, it is thought that many cases of EV-D68 induced disease 
including AFM in the US during the 2014 outbreak were associated with the newly emerging virus clades, includ-
ing the subclade B115. The appearance of these new variants may be a result of evolution of EV-D68 genome. 
It remains to be elucidated if the variable clinical presentations observed in this study were associated with an 
altered pathogenicity of the new subclade B3 virus or host factors, such as population structure and immunity.
A limitation of this study is that all the EV-D68 cases identified were based on NP specimens examined in a 
single institution, which might not reflect the true incidence of EV-D68 infection for the 2016 outbreak in this 
region. Also, only randomly selected NP specimens in September and October of 2015 (n = 199) and January 
through May of 2016 (n = 108) were analyzed for EV-D68. Given the high positivity rate (average of 29% and 
36% in 2014 and 2016, respectively) of EV-D68 detected during the outbreak, the results from randomly selected 
specimens most likely represent the prevalence of EV-D68 among the population in the specific study period.
In conclusion, we report here a new EV-D68 subclade B3 circulating in the US that caused an outbreak in 
the Lower Hudson Valley, New York with 160 laboratory-confirmed cases in 2016. It is unclear to date if our 
observation indicates local or nationwide activity of EV-D68 in 2016. The lack of detected EV-D68 disease and 
relatively few AFM cases in 2015 compared with the recent increase of EV-D68-related respiratory illness in 
the Netherlands, Sweden and now the Hudson Valley, NY and increased AFM case reports in the US in 2016 
potentially provides more evidence for a causative association between EV-D68 and AFM. This demonstrates the 
importance of providing accurate laboratory diagnostic testing for the detection of EV-D68 in clinical specimens. 
Clinicians, clinical laboratorians and public health agencies should be aware of the active circulation of EV-D68 
and its clinical implications.
Methods
Patients. Patients included in this study are those with respiratory illness and/or other medical conditions 
who visited or hospitalized in multiple medical facilities in the Lower Hudson Valley in September and October 
2015, and from January to October 2016. The majority of patients were those who visited the emergency depart-
ment or hospitalized at the Maria Fareri Children’s Hospital at Westchester Medical Center (WMC), a tertiary 
teaching hospital 25 miles north of New York City serving patients mainly in the Lower Hudson Valley, New York. 
All patients included had a nasopharyngeal swab or aspirate (NP) specimen collected and tested for multiple 
respiratory pathogens at the WMC Clinical Virology Laboratory.
For study subjects, only leftover nasopharyngeal swab specimens collected for testing of respiratory pathogens 
at the WMC Laboratory were used in this study. Methods were carried out in accordance with the Department 
of Health and Human Services CFR 45 Part 46 Protection of Human Subjects. The New York Medical College 
Institutional Review Board approved all experimental protocols of this study and granted a waiver for informed 
consent from patients.
Level of biocontainment. Enterovirus D68 in the Picornaviridae family belongs to biological risk group 
2 microorganism per the US National Institute of Health (http://osp.od.nih.gov/office-biotechnology-activities/
www.nature.com/scientificreports/
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biosafety/biosafety-guidance). This study was carried out in certified biosafety level 2 laboratories in accordance 
with current CDC and institutional biosafety guidelines. All primary clinical specimens were processed in a Class 
II biosafety cabinet. No viral culture was performed.
FilmArray Respiratory panel assay. NP specimens were collected into tubes each with 1-mL of viral 
transport medium (Diagnostic Hybrid, San Diego, CA) and were analyzed for the presence of rhinovirus/enter-
ovirus (RhV/EV) and other respiratory pathogens using the FilmArray Respiratory Panel (RP) kit (version 2.0,) 
on the FilmArray instrument (v2.0, BioFire Inc., Salt Lake City, UT).
Selection of specimen for EV-D68 analysis. NP specimens were selected by the following criteria and 
further analyzed using an EV-D68-specific rRT-PCR and NGS: (1) all RhV/EV-positive NP specimens by the 
RP assay that were collected between June 1, 2016 and October 31, 2016; (2) randomly selected representative 
RhV/EV-positive NP specimens that were collected from January through May 2016 (approximately 25%); (3) 
randomly selected representative RhV/EV-negative NP specimens that were collected from January to October 
2016. For comparison, all RhV/EV-positive NP specimens collected in September and October 2015 were also 
included. For patients with multiple NP specimens examined during the study period, only the first NP specimen 
was included in the final analysis for EV-D68.
EV-D68 real-time RT-PCR assay. The EV-D68 rRT-PCR was performed as described previously34. Total 
RNA was extracted from leftover NP specimens (≤150 µl) using the EZ1 Virus Mini kit, v2.0 (Qiagen, Valencia, 
CA) on the EZ1 Advanced XL instrument (Qiagen) without carrier RNA. RNA was eluted in 60 µl of buffer. A 
single-step reverse transcription PCR was carried out on either ABI 7500 Fast Dx or ViiA7 real-time PCR system 
(Life Technologies, Carlsbad, CA). A positive EV-D68 was defined for a sample exhibiting an exponential ampli-
fication and with a cycle threshold (Ct) of ≤40.0.
Metagenomic Next-Generation Sequencing. Representative RhV/EV-positive and negative NP spec-
imens were analyzed by a shotgun metagenomic NGS using the MiSeq system (Illumina, San Diego, CA) as 
described previously29, 35, with an exception that paired-end sequencing was performed as 2 × 76 base pairs 
(bp). Raw sequence reads were aligned and curated using a reference genome (strain NY120, accession number 
KP745751) from a 2014 patient.
Phylogenetic analysis. Complete or nearly complete genomes from 341 EV-D68 strains, including 22 
obtained from this outbreak and three from patients in Florida, Texas and New York as reported by the CDC in 
201637, were included in comparative genome analysis. Sequences downloaded from the GenBank or obtained 
in this study were aligned, and a phylogenetic tree based on genome sequences was constructed using the 
unweighted pair-group method with arithmetic averages (UPGMA) clustering method with the BioNumerics 
software (version 7.6, Applied Maths, Belgium). The amino acid polymorphisms and substitutions identified by 
sequence analysis were plotted on graphs using the WebLogo 3.5.038.
Statistical analysis. Fisher’s exact test was used to compare the pediatric ICU admission rate between 2014 
and 2016 using the Prism GraphPad software (version 7, La Jolla, CA).
Nucleotide sequence accession numbers. Complete genomes of 22 EV-D68 strains from this 2016 out-
break have been deposited to the NCBI GenBank database with accession numbers KX957754 to KX95776236, 
and KY385880 to KY385892.
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